Renal Franchise

Our robust pre-clinical program includes a therapeutic platform targeting nucleophosmin (NPM), a protein which becomes toxic when the cell is injured inducing the regulated cell death pathway that leads to organ failure.  We have a first-in-class drug in development that prevents and treats NPM-induced cell death.  This forms the foundational building block for our kidney franchise.  

​

Given the high unmet medical need, the first indication we are pursuing is Acute Kidney Injury (AKI) where we have already demonstrated efficacy, safety and survival benefit in pre-clinical studies and are advancing a peptide therapeutic towards IND.  This common and often fatal disease affects over 78 million patients globally each year and leaves surviving patients with cardio-renal disease, often leading stroke, myocardial infarction, chronic kidney disease or end stage renal disease.  

There is currently no treatment available other than supportive care.